Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in adult axial spondyloarthritis with remission-withdrawal period
2022-501018-78-00Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in axial spondyloarthritis (axSpA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) (6 arms), sponsored by AbbVie Inc. Primary endpoint: ASAS40 response at Week 14. Started Mar 2020; status: completed.
02
Drugs
upadacitinib
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on 2022-501018-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501018-78-00.